4
Participants
Start Date
February 10, 2023
Primary Completion Date
July 12, 2023
Study Completion Date
July 12, 2023
ANV419
ANV419 administered by intravenous (IV) infusion
Lenalidomide with low-dose dexamethasone
Lenalidomide and dexamethasone administered orally
Daratumumab
Daratumumab administered by subcutaneous injection
Hospital Universitario La Princesa, Madrid
Vejle Hospital, Vejle
Institut Paoli-Calmettes, Marseille
CHU de Nantes - Hôtel-Dieu, Nantes
Institut de cancérologie Strasbourg Europe (ICANS), Strasbourg
Hospital Clinic Barcelona, Barcelona
Hospital General Universitario Morales Meseguer, Murcia
Hospital Clinico Universitario de Salamanca, Salamanca
Inselspital, Universitätsspital Bern, Bern
Kantonsspital St. Gallen, Sankt Gallen
Universitätsklinikum Jena, Jena
Lead Sponsor
Anaveon AG
INDUSTRY